Sign up USA
Proactive Investors - Run By Investors For Investors

Quest Diagnostics’ Subsidiary Receives FDA Approval For Simplexa Flu Test

Quest Diagnostics’ Subsidiary Receives FDA Approval For Simplexa Flu Test

Quest Diagnostics (NYSE: DGX), a provider of diagnostic testing services based in Madison, New Jersey, announced today that the U.S. Food and Drug Administration (FDA) has approved its Focus Diagnostics subsidiary’s Simplexa flu test. 

The Simplexa test is intended to help detect influenza A, influenza B and RSV infections, which can sometimes cause severe illnesses, especially in children.  These viruses can be hard to diagnose since their signs and symptoms are similar to other respiratory viruses. 

According to the U.S. Centers for Disease Control and Prevention, twenty five to 40 percent of infants and young children with RSV infection show signs of pneumonia or bronchiolitis, and it is estimated that between 75,000 and 125,000 children less than one year old are hospitalized each year due to RSV.

According to Quest, it is expected that results from the Simplexa test can be reported in less than three hours after receiving a virus specimen.   

"For many physicians and lab administrators, it will eliminate the time-consuming step of sending a specimen to a reference lab for molecular testing to detect flu and RSV infection,” said John G. Hurrell, Vice President of Focus Diagnostics.

Also, results of a clinical study that was part of the FDA approval process found the Simplexa test performed comparably to other devices in detecting the target viruses.  

Since the announcement, the Quest’s share price has rallied 1.6% to trade at $50.12 as of 2:17 pm EST.

Register here to be notified of future DGX Company articles
View full DGX profile

Quest Diagnostics Timeline

Related Articles

July 14 2015
OptiBiotix is described as a “sweet opportunity” by the research house Hybridan, which recently started coverage of the AIM-listed company
June 16 2015
"There is a strong demand for efficiently delivered personalised health information."
September 22 2015
Venn plans to use deal to get more involved in early-stage drug development
Copyright ©, 2015. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC